HBIO stock forecast, quote, news & analysis

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HBIO moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 11 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 46 cases where HBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for HBIO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 42 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

HBIO broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on HBIO as a result. In 76 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 159 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

The Aroon Indicator entered an Uptrend today. In 79 of 108 cases where HBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.130) is normal, around the industry mean (4.955). P/E Ratio (-3.635) is within average values for comparable stocks, (40.806). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.